Business
TME Pharma Provides Results of Final Exercise of Warrants Z
BERLIN, June 27, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides results of the sixth and final exercise of Warrants Z and an update on the outstanding number of ordinary shares and Warrants Z as of the settlement date taking place today. The exercise of 1,948 Warrants Z has resulted in the issuance of 2,435 new shares
About this update from Tme Pharma N.v.
[{"type":"list","items":[{"val":[{"type":"text","content":"1,948 Warrants Z were exercised resulting in the issuance of 2,435 new ordinary shares","length":86,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":86,"olType":false},{"type":"text","content":"BERLIN, June 27, 2025--(BUSINESS WIRE)--Regulatory News:","length":56,"tagName":"p"},{"type":"text","content":"TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides results of the sixth and final exercise of Warrants Z and an update on the outstanding number of ordinary shares and Warrants Z as of the settlement date taking place today. The exercise of 1,948 Warrants Z has resulted in the issuance of 2,435 new shares for gross proceeds of €487.","length":488,"tagName":"p"},{"type":"text","content":"In the sixth and final Warrant Z exercise period, from May 26, 2025, to June 20, 2025, holders were entitled for every 4 Warrants Z held to subscribe for 5 new shares at €0.20 per share. Following this exercise, any Warrants Z that have not been exercised by the end of the last exercise period become null and void (see "Terms and Conditions of the Warrants" on the TME Rights Issue page for more details).","length":417,"tagName":"p"},{"type":"text","content":"The following numbers of TME Pharma securities are thus issued and outstanding:","length":79,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"ALTME ordinary shares (ISIN: NL0015000YE1): 94,188,981","length":54,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Warrants Z (ISIN: NL0015001SR3): 0 (zero)","length":41,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":95,"olType":false},{"type":"text","content":"Following the preferential rights issue with attached warrants launched on November 24, 2023, all six exercise periods in this warrant financing structure resulted in the exercise of a total of 997,584 Warrants Z and the subsequent issuance of a total of 1,246,980 new shares for gross proceeds of €249,396.","length":307,"tagName":"p"},{"type":"text","content":"Additional InformationThe characteristics, terms and conditions and dilution resulting from the transaction are summarized in the press releases published...